12 Effective Strategies for Improving Medication Adherence in Patients

Key Strategies for Improving Medication Adherence in Patients

• Simplify before you remind. Single-pill combinations and once-daily dosing remove adherence friction at the prescribing root - twice-daily dosing alone drops adherence ~7 points; four-times-daily drops it ~19.

• Cost is a cliff, not a slope. Abandonment runs under 5% at $0 out-of-pocket and rises to 60% above $500 per fill; eliminating post-MI copays cut major vascular events ~14% at no insurer cost.

• Two-way texting beats one-way reminders. SMS reminders double the odds of adherence, but the real unlock is the return reply - that's where cost, side-effect, and comprehension barriers actually surface.

• The pharmacist is the most underused adherence clinician you can engage - MTM has a documented 12-to-1 ROI, and three triple-weighted Star measures are now revenue-critical (4+ star achievement collapsed from 68% to 42% in two years).

• Close the discharge gap. Up to 40% of patients have medication discrepancies at discharge; pharmacy-led transitions-of-care reconciliation reduced 30-day readmissions in 89% of studies in one major review.

• Personalize by barrier type. Depression roughly doubles nonadherence odds; cost, side effects, beliefs, and comorbidity each require different interventions - uniform reminder protocols underperform.

• Treat SDOH as adherence drivers. Transportation gaps and food insecurity defeat clinical prescribing; CHW outreach has cut 30-day readmissions from 25.7% to 7.9% with a documented ~$2.47-per-$1 Medicaid ROI.

• Use AI to find risk, not to replace humans. Predictive analytics works when it routes patients to a pharmacist call, CHW visit, or copay assistance - not as a standalone intervention.

Simplify the Regimen Before You Reach for Reminders

The most powerful adherence intervention you can run is one that asks nothing of the patient.

Regimen complexity is the most modifiable structural driver of nonadherence - every additional daily dose adds cognitive friction, scheduling difficulty, and a fresh opportunity to skip.

Single-pill combinations and once-daily formulations attack the problem at the prescribing root instead of relying on willpower or reminder logistics.

A landmark 51-study meta-analysis found that twice-daily dosing produces a 6.7-percentage-point drop in taking-adherence compared with once-daily, and the gap widens to 19.2 points at four-times-daily.

The standard of care is moving in this direction.

In December 2025, the American Heart Association published its first scientific statement formally endorsing single-pill combinations for hypertension - a meaningful signal that the field now treats simplification as a first-line approach, not a fallback.

For health-system executives, the operational implication is straightforward: build EHR order sets that surface SPCs first for hypertension, dyslipidemia, and HIV, and pair them with once-daily formulations wherever clinically equivalent options exist.

The context that makes this urgent: more than 40% of older Americans now take five or more prescription medications, and roughly one in five takes ten or more - a tripling over the past two decades.

Reducing pill count before you build the reminder program is the highest-ROI sequence.

Confirm Understanding with Teach-Back

You can hand a patient a perfect prescription and still lose adherence at the door of the exam room.

Patients forget 40 to 80% of medical information the moment they leave a visit, and nearly half of what they do retain is incorrect.

More than 60% misunderstand prescription directions immediately after the doctor leaves the room.

The fix is one of the cheapest interventions in healthcare.

Teach-back - asking the patient to explain the medication, the dose, and the schedule back to you in their own words - is a well-established, evidence-based health literacy intervention.

In one CABG cohort, 96% of patients rated it "effective or highly effective."

This is not abstract.

Roughly 36% of US adults - more than 75 million people - read at a basic or below-basic health literacy level.

Embed teach-back prompts into your EHR templates, your discharge workflows, and your specialty pharmacy counseling scripts.

It costs nothing, takes a minute, and converts a one-way information transfer into a closed loop of confirmed understanding.

Rebuild the Provider–Patient Conversation

Patients who feel unheard form weaker therapeutic alliances and disengage from medication regimens - especially the asymptomatic ones like statins and antihypertensives that produce no felt benefit.

The data on the clinical encounter itself is sobering.

Physicians interrupt patients at a median of 11 seconds into their opening statement, only 36% invite the patient to set the agenda, and specialists interrupt 80% of the time.

When patients are allowed to finish, they need just six seconds on average.

Six seconds is not a meaningful intrusion on visit time.

The implication for your organization is upstream.

Adherence cannot be solved at the pharmacy counter or through reminder texts if the originating clinical conversation is broken.

Communication training, agenda-setting protocols, and motivational interviewing - a goal-aligning communication style with strong systematic-review evidence - shift the cause-and-effect chain that drives every downstream adherence behavior.

Anchor Each Prescription to a Patient-Owned Goal

The most important thing a patient brings to a medication regimen isn't memory.

It's belief.

Across a 94-study meta-analysis of medication beliefs, nonadherence behavior is strongly associated with lower belief in a medication's necessity and higher concerns about it.

Forgetfulness is real, but belief in necessity is the dominant cognitive driver.

You can see the same pattern in the so-called white-coat effect.

Glaucoma patients' adherence rises measurably in the days leading up to a clinical visit and decays afterward - proximity to a goal-aligning encounter shifts behavior in real time, which is evidence that the conversation itself does the work.

Shared decision-making translates an abstract prescription into an instrumental act toward an outcome the patient personally owns - avoiding a stroke, preserving a transplanted kidney, staying independent at home.

For chronic asymptomatic conditions where the medication produces no day-to-day benefit, this goal-anchoring conversation is the single best defense against the predictable persistence drop-off at three, six, and twelve months.

Address the Affordability Cliff

Cost is the most direct, immediately fixable adherence barrier - and it behaves like a cliff, not a slope.

Prescription abandonment runs under 5% when patients pay nothing out of pocket.

It climbs to 45% at copays above $125, and to 60% above $500 per fill.

The clearest demonstration of what happens when you remove the cost barrier came from a 5,855-patient randomized trial of post-MI cardiovascular medications.

Eliminating copays raised adherence by 4 to 6 percentage points across beta-blockers, statins, and ACE/ARBs - and cut major vascular events by roughly 14% at no additional insurer cost.

Policy is starting to catch up.

The Inflation Reduction Act's $2,000 Medicare Part D out-of-pocket cap (rising to $2,100 in 2026) is a real-world adherence intervention at policy scale, projected to save roughly 11 million enrollees an average of $600 each.

Don't model the cap in isolation, though - plans are simultaneously raising deductibles and shifting more spending to coinsurance, and many beneficiaries may actually pay more in total.

For Medicare-heavy systems, the play is to pair the cap with copay assistance programs, 340B-leveraged dispensing where eligible, and value-based insurance design negotiations modeled on the post-MI trial - so the affordability advantage actually lands with the patient who needs it.

Make the Pharmacist a Frontline Adherence Clinician

For any organization that owns or contracts with pharmacy capability - a health system with retail or specialty pharmacy operations, an ACO with PBM relationships, an ASC parent group with outpatient dispensing - the pharmacist is your most underused adherence clinician.

They're clinically licensed, payer-recognized for Medication Therapy Management and Comprehensive Medication Review, and positioned exactly where adherence breaks down.

The financial case is direct.

Pharmacist-led MTM has a documented 12-to-1 ROI with measurable improvements in cholesterol management and therapy-goal achievement, and a systematic review of MTM programs has shown statistically significant clinical improvements across diabetes, hypertension, and dyslipidemia.

For your Medicare Advantage relationships and risk-bearing contracts, the stakes are now much higher than they were two years ago.

Three CMS Star Ratings adherence measures - statins, RAS antagonists, and oral diabetes medications - are triple-weighted.

Plans earning four stars or above receive a 5% quality bonus payment, and those payments totaled more than $12.8 billion in 2023 alone.

The share of MA-PD plans earning at least four stars collapsed from 68% in 2022 to 42% in 2024.

The threshold is moving away from plans, fast.

Engaging pharmacists in collaborative practice - alongside nurses, care managers, and physicians - converts adherence from a passive "did they fill it?" question into an active "is this working?" intervention that drives revenue-relevant Star performance.

Synchronize Refills with an Appointment-Based Model

If your network includes pharmacy partners, Appointment-Based Medication Synchronization is one of the few interventions in the literature with consistent positive evidence on the triple-weighted Star adherence measures.

It works in three ways at once: it cuts refill friction down to a single pharmacy trip, embeds a pharmacist comprehensive review into a predictable cadence, and anchors patient behavior around a fixed monthly appointment.

The results are unusually consistent.

Synchronization programs achieve PDC of 80% or higher in nearly all enrolled patients - 100% in oral diabetes, roughly 98% in RAS antagonists, and 98% in statins - compared with 74 to 80% under usual care.

Published evidence consistently shows 2.3 to 3.6 times higher adherence odds, with the gains running about three times larger in patients who started with low baseline adherence.

There's an established operational playbook - the Appointment-Based Model Implementation Guide - that offers a turn-key workflow your pharmacy partners can deploy without inventing the model from scratch.

Default to Two-Way SMS for Reminders and Follow-Up

Texting is the highest-ROI, lowest-friction adherence technology available in 2026, and the evidence has hardened.

A meta-analysis of 16 randomized trials covering 2,742 patients found that text-message reminders doubled the odds of adherence - a 17.8-percentage-point absolute increase, moving adherence from roughly 50% to nearly 68%.

The reach is unmatched.

SMS open rates in healthcare run around 98%, with 90% read within three minutes, compared with 20 to 28% for email.

Texting requires no app download, no portal login, and no broadband - a critical equity property when serving Medicaid, dual-eligible, and rural populations who can't be reliably reached through patient portals.

It's also worth knowing what doesn't work: the largest rigorous trial of higher-friction tech - smart pill bottles paired with financial incentives and social support, in over 1,500 post-MI patients - produced no significant improvement against usual care.

The bottleneck in adherence is contact and context, not the measurement of pill-taking.

The single feature that matters more than any other is whether the texting is genuinely two-way.

A one-way reminder tells you nothing about why a patient isn't filling.

A two-way conversation surfaces the reason - and surfacing the reason is where the actual adherence intervention lives.

We saw this play out directly in one of our own case studies.

A patient discharged from Hackensack Meridian Mountainside Medical Center after a stroke received an automated post-discharge text through our platform reminding her to take her newly prescribed anticoagulant.

She replied - through the two-way channel - that she hadn't filled the prescription because she couldn't afford it, and that she was feeling lightheaded.

The care team intervened immediately with a coupon for a free 30-day supply and a scheduled primary-care follow-up.

The likely readmission did not happen - an outcome that is functionally impossible with a one-way reminder system.

Read the full case study

Are You Screening for Depression in Your Adherence Workup?

If you're investigating why a patient isn't taking their medications, comorbid depression should be near the top of the list.

A foundational meta-analysis found that depression roughly doubles the odds of medication nonadherence - a 16-percentage-point absolute risk difference - and the elevated risk persists across diabetes, hyperlipidemia, hypertension, and other chronic conditions, ranging from 1.73 to 1.80 times baseline.

Social environment matters too.

A 254,144-patient analysis found that patients whose family members were fully adherent had a 37% full-adherence rate, compared with 27% for patients whose family members were not - roughly a 10-point lift from the household effect alone.

This is why uniform reminder protocols underperform.

The patient who skips because of side effects is a fundamentally different problem from the patient who skips because of depression, or because they don't believe the medication will help.

Side effects are the primary reason 23% of patients cite for stopping a medication.

Segment your adherence-failure workups by barrier type - cost, side effects, beliefs, comorbidity - and your interventions land where the marginal return is actually highest.

Close the Discharge Gap with Pharmacy-Led Medication Reconciliation

The 7 to 30 days after discharge are the highest-risk adherence window your organization manages.

Regimens have just changed, patients are exhausted, and outpatient follow-up is often delayed.

Up to 40% of patients have medication discrepancies at discharge, and 26% of hospital readmissions are medication-related and potentially avoidable.

Structured reconciliation closes the inpatient-to-outpatient gap.

Pharmacy-led transitions-of-care interventions reduced 30-day readmissions in 89% of studies in one major review - a level of consistency that's rare in adherence research, where most interventions are individually modest.

The regulatory and reimbursement tailwinds make this one of the easier business cases to build.

The Transitions of Care HEDIS measure has been fully phased into Medicare Advantage Star Ratings since 2022, requiring documented medication reconciliation within 30 days of discharge.

TCM CPT codes 99495 and 99496 make pharmacy-led TOC clinically necessary and financially viable.

One of our own case studies makes the operational version of this concrete.

A Fortune 100 hospital established a dedicated task force to lower readmission rates and chose our two-way texting platform specifically as part of a strategy to boost adherence to medication and discharge instructions.

The results: an 18-fold reduction in readmission risk, zero readmission penalties in FY24, and a 98% improvement in the team's ability to identify high-risk patients.

The payoff is direct reimbursement preservation in a year where every readmission penalty hits the operating margin.

Read the full case study

Treat Social Determinants of Health as Adherence Drivers

A patient who can't get to the pharmacy, who must choose between food and a copay, or who has no stable housing will not be reliably medication-adherent - regardless of how clinically perfect the prescription is.

The numbers among Medicare Part D beneficiaries make the scale clear.

35% report transportation difficulties and 22% report food insecurity, and both are significantly associated with elevated nonadherence.

The strongest evidence for what to do about it comes from a randomized trial of community health workers.

30-day readmission rates dropped from 25.7% to 7.9%, CHW-supported patients were 52% more likely to see a primary-care physician within two weeks of discharge, and the program has documented a Medicaid ROI of roughly $2.47 for every $1 invested.

For FQHCs, safety-net hospitals, and any Medicaid-heavy system, deploying community health workers is among the very few evidence-based interventions that produce both documented positive ROI and equity gains in the same intervention.

If your population mix includes meaningful Medicaid or dual-eligible volume, this isn't peripheral - it's structural.

Use Predictive Analytics to Find Tomorrow's Nonadherent Patient

Predictive analytics doesn't take pills for patients.

What it does is answer the "who do we call this week?" question that has historically been answered by clinical intuition alone.

Plans and PBMs are increasingly deploying AI to identify patients within 30 days of falling below the 80% PDC threshold, where Star Rating cut-points now sit deep inside the 90s for the diabetes adherence measure.

The margin for error has narrowed to almost nothing.

Vendor-reported results are real but should be read with care.

One twelve-hospital system has reported a 10.3% reduction in 30-day readmissions, $4.2 million in annual savings, and a 472% ROI from a predictive risk-scoring deployment.

Those are industry-sourced figures, not peer-reviewed outcomes.

Two cautions for capital allocators.

The widely cited consulting projections of $200 to $360 billion in annual AI healthcare savings are forward-looking estimates, not measured outcomes.

And the broader evidence is unambiguous: tech without redesigned care has repeatedly failed in large rigorous trials.

The real opportunity is AI plus human follow-up - a pharmacist call, a CHW visit, a targeted copay-assistance offer - not AI alone.

Make Every Discharge Reminder a Two-Way Conversation

You just read twelve strategies - and the through-line is that adherence is solved at the point where a patient can reply, not just receive a reminder.

That's what Dialog Health's HIPAA-compliant two-way texting platform is built for, and it's why systems like the Fortune 100 hospital we work with eliminated their FY24 readmission penalties and cut readmission risk 18-fold.

Our platform also delivers 82% readmission reduction, 95–97% open rates, and full integration with Epic, Cerner, Athena, Meditech, NextGen, and more.

What happens next: Fill out this quick form and one of our healthcare communication experts will reach out to schedule a brief 15-minute video call at your convenience.

We've done this hundreds of times with health systems just like yours, and you'll get all the information you need - no pressure, no commitment.

P.S. - If you're already running SMS reminders, the 15 minutes will show you exactly where two-way conversations close the adherence gaps one-way blasts can't.

Brandon Daniell, Co-Founder	Written by Brandon Daniell                                                              Brandon has more than 15 years of business and program development experience in healthcare. Worked with some of the leading employers, physicians, payors, and hospital systems, including GTE (now Verizon), BCBS of TN, and Hospital Corporation of America.